2025
Association Between Relapse and Long-term Kidney Outcomes in IgA Nephropathy
Shen X, Chen P, Hui M, Li J, Hou W, Yang H, Li Y, Liu L, Shi S, Zhou X, Lv J, Zhang H. Association Between Relapse and Long-term Kidney Outcomes in IgA Nephropathy. Kidney Medicine 2025, 101104. DOI: 10.1016/j.xkme.2025.101104.Peer-Reviewed Original ResearchRelapse-free ratePredictors of relapseEndpoint eventsClinicopathological predictorsIgA nephropathyLong-term kidney outcomesAssociated with adverse outcomesNon-relapsing patientsNon-relapse groupCox regression analysisEnd-stage kidney diseaseCorticosteroid-induced remissionLikelihood of relapseLASSO Cox regressionIgAN relapseRelapse incidenceRelapsed patientsRelapse groupEGFR declineRelapse rateKidney outcomesProspective cohortRemissionRelapseClinicopathological indicatorsFill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012–2021
Steiger K, Swarna K, Herrin J, McCoy R. Fill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012–2021. Journal Of General Internal Medicine 2025, 1-8. PMID: 40760383, DOI: 10.1007/s11606-025-09784-0.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsType 2 diabetesBackgroundGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsCotransporter-2 inhibitorsFilling patternGlucose-lowering drugsAssociated with lower oddsAssociated with greater oddsCardiorenal comorbiditiesKidney benefitsReceptor agonistsKidney outcomesSodium-glucoseResultsThe studyHigher oddsLower oddsGreater oddsOlder ageOddsORGLP1RACKDASCVDKidneyEffects of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy
Guo Y, Ren Y, Shi S, Wang S, Zhou X, Liu L, Lv J, Zhu L, Zhang H. Effects of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy. Kidney Medicine 2025, 7: 101049. PMID: 40740727, PMCID: PMC12309955, DOI: 10.1016/j.xkme.2025.101049.Peer-Reviewed Original ResearchResponse to immunosuppressive therapyFoot process effacementImmunosuppressive therapyKidney prognosisSevere foot process effacementKidney outcomesRisk factorsIgA nephropathyEstimated glomerular filtration rateMonths of follow-upPodocyte injuryPeking University First HospitalComposite kidney outcomeIndependent risk factorGlomerular filtration rateImmunoglobulin A nephropathyEnd-stage kidney diseasePodocyte lesionsContinuous net reclassification improvementPodocyte foot process effacementIntegrated discrimination improvementNet reclassification improvementOverall cohortAbstractText Label="ExposureAbstractText Label="RESULTS"Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
Lee M, Sattar N, Pop-Busui R, Deanfield J, Emerson S, Inzucchi S, Mann J, Marx N, Mulvagh S, Poulter N, Badve S, Pratley R, Perkovic V, Buse J, McGuire D. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care 2025, 48: 846-859. PMID: 40156846, DOI: 10.2337/dc25-0241.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide 1 receptor agonistsPeptide 1 receptor agonistsComposite kidney outcomeGLP-1RAAll-Cause MortalityType 2 diabetesKidney outcomesLong-actingOral formulationOutcome trialsHazard ratioReduced incidence of MACEIncidence rates of MACEIncreased risk of severe hypoglycemiaMeta-analysis of randomized trialsLong-acting GLP-1RASystematic review of PubMedWorsening kidney functionRisk of severe hypoglycemiaIncidence of MACERate of MACEEvaluate renal functionAdverse cardiovascular eventsCardiovascular outcome trialsReview of PubMedRed blood cell casts on kidney biopsy and progression of IgA nephropathy
Yao Y, Tang C, Shi S, Chen P, Zhou X, Lv J, Liu L, Zhang H. Red blood cell casts on kidney biopsy and progression of IgA nephropathy. Nephrology Dialysis Transplantation 2025, 40: 1570-1579. PMID: 39909472, DOI: 10.1093/ndt/gfaf023.Peer-Reviewed Original ResearchComposite kidney endpointRed blood cell castsMedian Follow-UpImmunosuppressive therapyKidney endpointsCell castsFollow-upIgA nephropathyKidney diseaseProgression of IgA nephropathyDisease progression of patientsCox regression analysisEnd stage kidney diseaseKidney disease progressionAcute active lesionsStage kidney diseaseProgression of patientsRenal prognosisCrescentic lesionsDeath due to kidney diseaseKidney biopsyKidney outcomesUnivariate analysisActive lesionsMultivariate analysis
2024
Long-term outcomes of IgA nephropathy in China
Shen X, Chen P, Liu M, Liu L, Shi S, Zhou X, Lv J, Zhang H. Long-term outcomes of IgA nephropathy in China. Nephrology Dialysis Transplantation 2024, 40: 1137-1146. PMID: 39557651, DOI: 10.1093/ndt/gfae252.Peer-Reviewed Original ResearchConceptsEnd-stage kidney diseaseLong-term outcomesTime-averaged proteinuriaKidney outcomesPrognosis of immunoglobulin A nephropathyFollow-upMonths of follow-upKidney failureOutcome of IgA nephropathyAssociated with kidney failureKidney survival ratesPeking University First HospitalRestricted cubic spline analysisRisk of end-stage kidney diseaseLong-term kidney survivalBiopsy-proven IgANOutcome of IgANKaplan-Meier analysisAnnual event rateLong-term prognosisCurrent treatment strategiesImmunoglobulin A nephropathyRisk of kidney failureCubic spline analysisProteinuria remissionPrognosis of IgA nephropathy patient with proteinuria remission by supportive therapy: cohort from screening failed Chinese patients in TESTING study
Guo Y, Shi S, Zhao J, Wang C, Liu Z, Fu S, Chen N, Li G, Wang L, Ni Z, Zhang H, Lai L, Lv J, Zhang H. Prognosis of IgA nephropathy patient with proteinuria remission by supportive therapy: cohort from screening failed Chinese patients in TESTING study. Renal Failure 2024, 46: 2398826. PMID: 39248402, PMCID: PMC11385640, DOI: 10.1080/0886022x.2024.2398826.Peer-Reviewed Original ResearchConceptsRelapse of proteinuriaImmunosuppressive therapyComposite kidney outcomeKaplan-Meier analysisProteinuria remissionKidney outcomesFollow-upSupportive therapyKidney outcomes of patientsLong-term kidney outcomesRenin-angiotensin system blockersComposite kidney endpointRemission of proteinuriaOutcomes of patientsLong-term prognosisRun-in phaseIgA nephropathy patientsStages of follow-upIntensive supportive therapyEarly stage of follow-upPersistent remissionDialysis of patientsKidney survivalRenal transplantationKidney endpointsEffects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions
Siddiqi T, Cherney D, Siddiqui H, Jafar T, Januzzi J, Khan M, Levin A, Marx N, Rangaswami J, Testani J, Usman M, Wanner C, Zannad F, Butler J. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions. Journal Of The American Society Of Nephrology 2024, 36: 242-255. PMID: 39230974, PMCID: PMC11801753, DOI: 10.1681/asn.0000000000000491.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsType 2 diabetes mellitusChronic kidney diseaseEffects of sodium-glucose cotransporter-2 inhibitorsComposite kidney endpointCotransporter-2 inhibitorsKidney outcomesHeart failureKidney diseaseKidney endpointsHazard ratioDoubling of serum creatinineCombination of heart failureSustained doubling of serum creatininePlacebo-controlled trialReduced ejection fractionBaseline heart failureConfidence intervalsRandom-effects modelAlbuminuria progressionEjection fractionSerum creatinineReview ManagerMellitusPatientsPeak Tricuspid Regurgitation Jet Velocity and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
Oka T, Tighiouart H, McCallum W, Tuttle M, Testani J, Sarnak M. Peak Tricuspid Regurgitation Jet Velocity and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Kidney International Reports 2024, 9: 3035-3044. PMID: 39430198, PMCID: PMC11489825, DOI: 10.1016/j.ekir.2024.07.009.Peer-Reviewed Original ResearchLeft ventricular ejection fractionPulmonary artery pressureCreatinine doublingEGFR declineEjection fractionKidney outcomesHeart failurePeak tricuspid regurgitant jet velocityDoubling of serum creatinineTricuspid regurgitant jet velocityElevated pulmonary artery pressureAssociated with lower eGFRWorsening kidney functionVentricular ejection fractionRegurgitant jet velocityCox proportional hazards modelsProportional hazards modelPost Hoc AnalysisBaseline eGFRSerum creatinineLow eGFRTOPCAT trialFollow-upKidney functionArterial pressure413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk
NEUMILLER J, HERRIN J, SWARNA K, POLLEY E, GALINDO R, UMPIERREZ G, DENG Y, MICKELSON M, MCCOY R. 413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk. Diabetes 2024, 73 DOI: 10.2337/db24-413-p.Peer-Reviewed Original ResearchPatient-Centered Outcomes Research InstituteModerate CVD riskKidney composite outcomeAssociated with lower riskGLP-1RACVD riskType 2 diabetesKidney outcomesComposite outcomeKidney diseaseLow riskHigh riskInitiation of kidney replacement therapyEffects of glucose-lowering agentsCardiovascular diseaseHigh risk of cardiovascular diseaseAssociated with increased riskBaseline CVD riskAssociated with higher riskRisk of cardiovascular diseaseGlucose-lowering agentsCare of peopleIncident kidney diseaseModerate cardiovascular riskTarget trial frameworkTime-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study
Tang C, Chen P, Si F, Lv J, Shi S, Zhou X, Liu L, Zhang H. Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study. American Journal Of Kidney Diseases 2024, 84: 170-178.e1. PMID: 38364955, DOI: 10.1053/j.ajkd.2023.12.016.Peer-Reviewed Original ResearchComposite kidney outcomeProteinuria levelsKidney outcomesEnd-stage kidney diseaseFollow-upIgA nephropathyLong-term kidney outcomesHigh riskMonths of follow-upProgression of IgA nephropathyBaseline proteinuria levelsPeking University First HospitalMedian Follow-UpLevel of proteinuriaRisk of kidney failureTreatment of IgANProgression of IgANBaseline proteinuriaAbstractText Label="RATIONALECohort studyProteinuriaFirst HospitalKidney diseaseIgANSurrogate endpointsDecline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang J, de Boer R, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 144-152. PMID: 37952176, PMCID: PMC10641768, DOI: 10.1001/jamacardio.2023.4664.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsEGFR declineGlomerular filtration rateEjection fractionHeart failurePrespecified analysisFiltration rateMonths 1Estimated glomerular filtration rateDapagliflozin-treated patientsKidney composite outcomePrimary cardiovascular outcomeHeart Failure TrialChronic kidney diseaseCotransporter 2 inhibitorsInternational multicenter studyLives of patientsBaseline eGFRKidney eventsKidney outcomesCardiovascular outcomesComposite outcomePrognostic factorsFailure TrialMulticenter study
2023
Association of Pulmonary Arterial Pulsatility Index (PAPi) with Kidney Outcomes Among Patients Admitted for Acute Decompensated Heart Failure
Tuttle M, Tighiouart H, Testani J, Banlengchit R, Moises A, Sarnak H, Oka T, Kiernan M, Sarnak M, McCallum W. Association of Pulmonary Arterial Pulsatility Index (PAPi) with Kidney Outcomes Among Patients Admitted for Acute Decompensated Heart Failure. Journal Of The American Society Of Nephrology 2023, 34: 144-145. DOI: 10.1681/asn.20233411s1144d.Peer-Reviewed Original ResearchA Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Ndumele C, Neeland I, Tuttle K, Chow S, Mathew R, Khan S, Coresh J, Baker-Smith C, Carnethon M, Després J, Ho J, Joseph J, Kernan W, Khera A, Kosiborod M, Lekavich C, Lewis E, Lo K, Ozkan B, Palaniappan L, Patel S, Pencina M, Powell-Wiley T, Sperling L, Virani S, Wright J, Singh R, Elkind M, Rangaswami J, Association O. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation 2023, 148: 1636-1664. PMID: 37807920, DOI: 10.1161/cir.0000000000001186.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseMetabolic risk factorsMetabolic syndromeRisk factorsKidney diseaseCardiovascular diseaseSocial determinantsEarly life preventionUnique management considerationsManagement of patientsInterdisciplinary care modelAmerican Heart AssociationBiological risk factorsScientific statementKidney outcomesLifestyle modificationHeart AssociationClinical managementCare modelClinical careSyndromeClinical phenotypeDiseaseMajor guidelinesWeight lossUrinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials
Kiernan E, Hu D, Philbrook H, Ix J, Bonventre J, Coca S, Moledina D, Fried L, Shlipak M, Parikh C. Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials. American Journal Of Kidney Diseases 2023, 83: 151-161. PMID: 37726051, PMCID: PMC10841767, DOI: 10.1053/j.ajkd.2023.07.012.Peer-Reviewed Original ResearchAcute kidney injuryKidney injuryClinical trialsSerum creatinineUrinary biomarkersAKI eventsVA NEPHRONCombination armUrine biomarkersDiabetic chronic kidney disease patientsChronic Kidney Disease trialChronic kidney disease patientsAldosterone system blockadeCombination therapy armKidney Disease TrialRAAS inhibitor therapySafety end pointCombination therapy groupKidney disease patientsBiomarkers of injuryAKI incidenceKidney outcomesMonotherapy armRAAS blockadeRAASi therapyMesangial C3 Deposition, Complement-Associated Variant, and Disease Progression in IgA Nephropathy
Kang Y, Xu B, Shi S, Zhou X, Chen P, Liu L, Li Y, Leng Y, Lv J, Zhu L, Zhang H. Mesangial C3 Deposition, Complement-Associated Variant, and Disease Progression in IgA Nephropathy. Clinical Journal Of The American Society Of Nephrology 2023, 18: 1583-1591. PMID: 37651123, PMCID: PMC10723908, DOI: 10.2215/cjn.0000000000000290.Peer-Reviewed Original ResearchConceptsMesangial C3 depositionGenome-wide association studiesIgA nephropathyComplement factor HC3 depositionGenotype-phenotype correlationIntensity of C3 depositionAssociation studiesLong-term kidney outcomesSusceptibility variantsProgression of IgA nephropathySevere clinical phenotypeKaplan-Meier analysisDeposition of IgAIgA nephropathy cohortIgA nephropathy progressionComplement component 3Chi-square testPrimary GNClinical phenotypeKidney outcomesFactor HGenotypesChinese patientsComplement regulatorsEvaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19
Menez S, Coca S, Moledina D, Wen Y, Chan L, Thiessen-Philbrook H, Obeid W, Garibaldi B, Azeloglu E, Ugwuowo U, Sperati C, Arend L, Rosenberg A, Kaushal M, Jain S, Wilson F, Parikh C, Consortium T, Deng J, Atta M, Bagnasco S, Ko A, Iwasaki A, Farhadian S, Nelson A, Casanovas-Massana A, White E, Schulz W, Coppi A, Young P, Nunez A, Shepard D, Matos I, Strong Y, Anastasio K, Brower K, Kuang M, Chiorazzi M, Bermejo S, Vijayakumar P, Geng B, Fournier J, Minasyan M, Muenker M, Moore A, Nadkarni G. Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19. American Journal Of Kidney Diseases 2023, 82: 322-332.e1. PMID: 37263570, PMCID: PMC10229201, DOI: 10.1053/j.ajkd.2023.03.010.Peer-Reviewed Original ResearchConceptsSoluble tumor necrosis factor receptor 1Major adverse kidney eventsAdverse kidney eventsAdverse kidney outcomesAcute kidney injuryKidney eventsTumor necrosis factor receptor 1Necrosis factor receptor 1Plasma biomarkersKidney outcomesC-indexFactor receptor 1Hospitalized patientsCOVID-19KDIGO stage 3 acute kidney injuryDialysis-requiring acute kidney injuryStage 3 acute kidney injuryLong-term adverse health outcomesReceptor 1Long-term kidney dysfunctionAvailable blood samplesIdentification of patientsProportional hazards regressionAdverse health outcomesCOVID-19 hospitalizationWCN23-0514 Long-term kidney outcomes following pediatric acute kidney injury not receiving dialysis: A population-based propensity-matched cohort study
Robinson C, Jeyakumar N, Luo B, Askenazi D, Garg A, Goldstein S, Greenberg J, Mammen C, Nash D, Parekh R, Silver S, Thabane L, Wald R, Zappitelli M, Chanchlani R. WCN23-0514 Long-term kidney outcomes following pediatric acute kidney injury not receiving dialysis: A population-based propensity-matched cohort study. Kidney International Reports 2023, 8: s8-s9. DOI: 10.1016/j.ekir.2023.02.019.Peer-Reviewed Original ResearchDapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Docherty K, Fang J, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 56-65. PMID: 36326604, PMCID: PMC9634592, DOI: 10.1001/jamacardio.2022.4210.Peer-Reviewed Original ResearchConceptsBaseline kidney functionKidney composite outcomeEffect of dapagliflozinEjection fractionHeart failureKidney outcomesComposite outcomePrimary outcomeKidney functionKidney diseaseSodium-glucose cotransporter 2 inhibitorsBaseline eGFR categoryBaseline kidney diseaseBenefit of dapagliflozinComposite kidney outcomeHeart Failure TrialReduced ejection fractionCotransporter 2 inhibitorsHeart failure eventsGlomerular filtration rateOverall incidence rateOverall event rateLives of patientsTreatment effectsEGFR categories
2022
Multi-Scalar Data Integration Links Glomerular Angiopoietin-Tie Signaling Pathway Activation With Progression of Diabetic Kidney Disease
Liu J, Nair V, Zhao Y, Chang D, Limonte C, Bansal N, Fermin D, Eichinger F, Tanner E, Bellovich K, Steigerwalt S, Bhat Z, Hawkins J, Subramanian L, Rosas S, Sedor J, Vasquez M, Waikar S, Bitzer M, Pennathur S, Brosius F, De Boer I, Chen M, Kretzler M, Ju W, Group F, Knight R, Lecker S, Stillman I, Bogen S, Amodu A, Ilori T, Maikhor S, Schmidt I, Beck L, Henderson J, Onul I, Verma A, Waikar S, McMahon G, Valerius M, Waikar S, Weins A, Colona M, Greka A, Hacohen N, Hoover P, Marshall J, Aulisio M, Chen Y, Janowczyk A, Jayapandian C, Viswanathan V, Bush W, Crawford D, Madabhushi A, Bush L, Cooperman L, Gonzalez-Vicente A, Herlitz L, Jolly S, Nguyen J, O’toole J, Palmer E, Poggio E, Sedor J, Sendrey D, Spates-Harden K, Taliercio J, Bjornstad P, Pyle L, Vinovskis C, Appelbaum P, Barasch J, Bomback A, Canetta P, D’Agati V, Kiryluk K, Kudose S, Mehl K, Shang N, Balderes O, Bansal S, Alexandrov T, Rennke H, El-Achkar T, Barwinska D, Bledsoe S, Borner K, Bueckle A, Cheng Y, Dagher P, Dunn K, Eadon M, Ferkowicz M, Herr B, Kelly K, Ferreira R, Quardokus E, Record E, Rivera M, Su J, Sutton T, Williams J, Winfree S, Menez S, Parikh C, Rosenberg A, Corona-Villalobos C, Wen Y, Johansen C, Rosas S, Roy N, Sun J, Williams M, Azeloglu E, Hansen J, He C, Iyengar R, Xiong Y, Prasad P, Srivastava A, Madhavan S, Parikh S, Rovin B, Shapiro J, Anderton C, Lukowski J, Pasa-Tolic L, Velickovic D, Oliver G, Ardayfio J, Bebiak J, Brown K, Campbell T, Campbell C, Hayashi L, Jefferson N, Roberts G, Saul J, Shpigel A, Stutzke C, Koewler R, Pinkeney R, Sealfon R, Troyanskaya O, Wong A, Tuttle K, Pollack A, Goltsev Y, Lucarelli N, Sarder P, Lake B, Zhang K, Boada P, Laszik Z, Nolan G, Anjani K, Sarwal M, Mukatash T, Sigdel T, Alloway R, Burg A, Lee P, Rike A, Shi T, Woodle E, Balis U, Blanc V, Conser N, Eddy S, Frey R, He Y, Hodgin J, Kretzler M, Lienczewski C, Luo J, Mariani L, Menon R, Otto E, Schaub J, Steck B, Elder M, Gilliam M, Hall D, Murugan R, Palevsky P, Randhawa P, Rosengart M, Tublin M, Vita T, Kellum J, Winters J, Alpers C, Berglund A, Blank K, Carson J, Daniel S, De Boer I, Dighe A, Dowd F, Grewenow S, Himmelfarb J, Hoofnagle A, Limonte C, McClelland R, Mooney S, Rezaei K, Shankland S, Snyder J, Wang R, Wilcox A, Williams K, Park C, Bansal S, Montellano R, Pamreddy A, Sharma K, Venkatachalam M, Ye H, Zhang G, Hedayati S, Kermani A, Lee S, Lu C, Miller R, Moe O, Patel J, Pillai A, Sambandam K, Torrealba J, Toto R, Vazquez M, Wang N, Wen N, Zhang D, Park H, Caprioli R, Patterson N, Sharman K, Spraggins J, Van de Plas R, Basta J, Diettman S, Gaut J, Jain S, Rauchman M, Vijayan A, Cantley L, Kakade V, Moledina D, Shaw M, Ugwuowo U, Wilson F, Arora T, Bitzer M, Brosius F, Gadegbeku C, Gipson D, Hawkins J, Kretzler M, Lienczewski C, Pennathur S, Troost J, Gadegbeku C, Bellovich K, Bhat Z, Massengill S, Perumal K. Multi-Scalar Data Integration Links Glomerular Angiopoietin-Tie Signaling Pathway Activation With Progression of Diabetic Kidney Disease. Diabetes 2022, 71: 2664-2676. PMID: 36331122, PMCID: PMC9750948, DOI: 10.2337/db22-0169.Peer-Reviewed Original ResearchConceptsEnd-stage kidney diseaseDiabetic kidney diseaseKidney diseaseAngiopoietin-2ANGPT2 levelsChinese cohort studyChronic kidney diseaseGlomerular filtration rateCardiovascular Health StudyPlasma angiopoietin-2High receptor expressionStandard clinical parametersSignaling Pathway ActivationPathway scoresThree-marker panelKidney outcomesCohort studyComposite outcomeClinical parametersEndothelial biomarkersFiltration rateReceptor expressionPrognostic biomarkerClinical phenotypingHealth Study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply